A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Trial Identifier: D8850C00010
Sponsor: AstraZeneca
NCTID:: NCT05375760
Start Date: June 2022
Primary Completion Date: October 2023
Study Completion Date: October 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish (US) Translation

Trial Locations